ABSTRACT
INTRODUCTION Over the past decade, the epidemiology of invasive fungal infections (IFIs) in transplant patients has evolved. The use of new antifungal drugs and modifications in transplant practices, including changes in surgical techniques, conditioning regimens, andnew immunosuppressive agents, has contributed to the shift in the numbers and types of IFIs encountered. To say the least, treatment of fungal disease in a complex transplant patient is challenging, and optimal outcome requires prompt diagnosis and consideration of several important factors including coinfection with immunomodulatory viruses, comorbid conditions, and drug interactions. The management of invasive mycoses within the complex milieu of the transplant recipient is discussed in this chapter.
